I'll be honest, my time surfing the East Coast is limited. But I've always had a soft spot for the surfers of New England, and that's in no small part due to the crew at Grain Surfboards and the ...
Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating ...
SOUTH SAN FRANCISCO - Senti Biosciences, Inc. (NASDAQ:SNTI), a biotechnology company currently trading near $1.95 and showing significant volatility according to InvestingPro data, announced it will ...
SENTI-202 is the Company's first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing ...
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell ...
The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results